
Affinia Therapeutics’ AFTX-201 Earns FDA Fast Track Designation for BAG3-Associated Dilated Cardiomyopathy
Affinia Therapeutics Granted FDA Fast Track Designation for AFTX-201 as a Treatment for People Living with BAG3-Associated Dilated Cardiomyopathy (DCM) Affinia Therapeutics an innovative gene therapy company with a pipeline of first-in-class and/or best-in-class adeno-associated virus (AAV) gene therapies initially…












